An investigation for investors in NASDAQ:PTLA shares was announced concerning possible securities laws violations in connection certain financial statements.
Investors who purchased shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether certain statements regarding by Portola Pharmaceuticals’ business, its prospects and its operations were materially false and misleading at the time they were made.
On February 26, 2016, Portola Pharmaceuticals Inc reported its fourth quarter and year end 2015 financial results and provided a corporate update. Portola Pharmaceuticals Inc reported that its annual total Revenue rose from $9.62 million in 2014 to $12.07 million in 2015, while its Net Loss increased from $137.12 million in 2014 to $226.50 million in 2015.
On March 24, 2016 Portola Pharmaceuticals Inc announced data from the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study, which evaluated the superiority of extended-duration anticoagulation with oral betrixaban compared with standard of care anticoagulation with injectable enoxaparin for the prevention of venous thromboembolism (VTE), or blood clots, in acute medically ill patients. Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) declined to as low as $18.20 per share on March 28, 2016.
On April 12, 2016, NASDAQ:PTLA shares closed at $23.67 per share.
Those who purchased NASDAQ:PTLA shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com